Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone Add-on in T2DM Inadequately Controlled with Metformin and Dapagliflozin
NCT04885712Phase 3Completed
- Sponsor
- Boryung
- Start
- May 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pioglitazone in type 2 diabetes mellitus (T2DM), sponsored by Boryung. Started May 2021; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04885712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04885712.